Establishing new use criteria led to an 86% reduction in the utilization of sugammadex with no appreciable impact on measured outcomes.
Jerry Rebo, PharmD, BCPS, BCCCP, DPLA
Advertisement
Articles by Jerry Rebo, PharmD, BCPS, BCCCP, DPLA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
FDA Approves First Drug for Pediatrics With Irritable Bowel Syndrome With Constipation
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
Regular Melatonin Supplementation May Hide Hidden Heart Complications
5
